PACE
Phage-assisted continous evolution
Introduction
Phage-assisted continuous evolution (PACE) is a powerful in vivo directed evolution method invented by Kevin Esvelt (now at the MIT media lab) and David Liu (Harvard University)
During PACE, the POI-encoding phages are propagated of E. coli host cells carrying two plasmids. One it the mutagenesis plasmid (MP), which encodes highly mutagenic genes strongly reducing phage replication fidelity and error repair. As these genes are toxic to the E. coli host, they are set under control of an arabinose-inducible pBAD promoter. Different MP variants have been reported, which cause mutation rates up to ~2.3 substitutions per kb during phage replication when fully inducedRN159 , thereby highly accelerating the evolution.
The second plasmid is called accessory plasmid (AP), and is the PACE component inducing the selection pressure directing the evolution towards the desired goal. The AP thereby encodes gene III, the aforementioned essential M13 gene required for phage replication. Importantly, gene III expression from the AP is made dependent on the function of the phage-encoded POI, e.g. via a synthetic circuit. In other words: the AP induces a selection pressure towards optimizing POI for the function required to activate gene III expression. In the simple case of evolving a transcription factor as depicted in Figure 1, gene III would simply be expressed from the promoter (“pTarget”) the transcription factor should be optimized for.
PACE employs a custom bioreactor setup and complex flow controls to achieve continuous in vivo directed evolution of the phage gene pool (Figure 2). The PACE setup comprises four major compartments: medium tank, turbidostat, lagoon and waste tank. The turbidostat thereby which contain “fresh” E. coli host cells (transformed with AP and MP) cultivated at constant cell density and in the absence of arabinose, so that the toxic MP-encoded genes are not expressed. The “lagoon” is the compartment in which the actual evolution takes place, i.e. where the phages infect the host cells and propagate, provided the encoded POI activates gene III on the AP. In addition, the medium in the lagoon is supplemented by arabinose via a corresponding inducer supply line. The lagoon is thereby kept under constant flux (typically ~1 lagoon volume per hour), i.e. fresh host cells are introduced from the turbidostat the identical volume is simultaneously going to the waste line. Thereby, phages which are inefficiently propagating (i.e. due to low fitness of their encoded POI) are washed out, while highly propagating (i.e. fit) variants take over the gene pool and further evolve.
The second plasmid is called accessory plasmid (AP), and is the PACE component inducing the selection pressure directing the evolution towards the desired goal. The AP thereby encodes gene III, the aforementioned essential M13 gene required for phage replication. Importantly, gene III expression from the AP is made dependent on the function of the phage-encoded POI, e.g. via a synthetic circuit. In other words: the AP induces a selection pressure towards optimizing POI for the function required to activate gene III expression. In the simple case of evolving a transcription factor as depicted in Figure 1, gene III would simply be expressed from the promoter (“pTarget”) the transcription factor should be optimized for.
PACE employs a custom bioreactor setup and complex flow controls to achieve continuous in vivo directed evolution of the phage gene pool (Figure 2). The PACE setup comprises four major compartments: medium tank, turbidostat, lagoon and waste tank. The turbidostat thereby which contain “fresh” E. coli host cells (transformed with AP and MP) cultivated at constant cell density and in the absence of arabinose, so that the toxic MP-encoded genes are not expressed. The “lagoon” is the compartment in which the actual evolution takes place, i.e. where the phages infect the host cells and propagate, provided the encoded POI activates gene III on the AP. In addition, the medium in the lagoon is supplemented by arabinose via a corresponding inducer supply line. The lagoon is thereby kept under constant flux (typically ~1 lagoon volume per hour), i.e. fresh host cells are introduced from the turbidostat the identical volume is simultaneously going to the waste line. Thereby, phages which are inefficiently propagating (i.e. due to low fitness of their encoded POI) are washed out, while highly propagating (i.e. fit) variants take over the gene pool and further evolve.
This aforementioned in vivo evolution setup has several advantages as compared to alternative directed evolution methods:
These key features enable render PACE a powerful tool for directed evolution in various application contexts. PACE has, for instance, been successfully applied for re-directing T7 polymerase target promoter specificityRN44' , for improving transcription activator-like effector nucleasesLiu2015 , evolving T7-based, modular biosensorsRN158 or proteases with novel specifiespacker2017 . In addition, PACE has been employed for studying drug-resistance development based on proteasesDickinson.2014 . Of note, strategies for applying both, positive and negative selection pressure during evolution in PACE have also been exploredCarlson.2014 .
Encouraged by the aforementioned, exciting work by others, we wanted to set up PACE in our lab to harness its power for directed evolution of proteins for human benefit. However, PACE turned out to be more difficult to run than anticipated initially. This was mainly due to the required, complex bioreactor setup. In fact, before we ran our first (and so far only) successful PACE experiment, we had already performed a high number of unsuccessful PACE runs (see the “Troubleshooting PACE” section further below). The major failure points for us were
In this work, we aimed at evolving a split T7 polymerase toward improved auto-reassembly. As we were still troubleshooting our PACE setup when this project began, we initially planned to employ our PREDCEL protocol to for directed in vivo evolution of the split T7. That is why you will find parts of our results also in the protein interaction subpage. However, we gained confidence in using PACE just when the corresponding split T7 encoding phages and APs were ready. Therefore, we decided to give it a try and – luckily – we were successful (read on).
- Due to the small phage size, their fast generation time and high mutation rates during replication, large and diverse gene pools can be generated to efficiently sample the space of possible, beneficial mutations
- A GOI’s fitness is evaluated in many different host cells due to its fast transfer between cells via the phage intermediate, thereby decoupling evolution form a particular host cell context
These key features enable render PACE a powerful tool for directed evolution in various application contexts. PACE has, for instance, been successfully applied for re-directing T7 polymerase target promoter specificity
- Cross-contamination with phages very well propagating on the used AP
- Quick phage wash out due to insufficient phage propagation in the lagoon
- Problems to reliably control cell density in the turbidostat
In this work, we aimed at evolving a split T7 polymerase toward improved auto-reassembly. As we were still troubleshooting our PACE setup when this project began, we initially planned to employ our PREDCEL protocol to for directed in vivo evolution of the split T7. That is why you will find parts of our results also in the protein interaction subpage. However, we gained confidence in using PACE just when the corresponding split T7 encoding phages and APs were ready. Therefore, we decided to give it a try and – luckily – we were successful (read on).
PACE Methods
Figure 3 shows a detailed, interactive PACE scheme. You can klick on the different components to receive information about the individual components of our PACE setup. Figure 4 and 5 show the different components of our custom-made PACE setup as it is standing in our lab right now. The accompanying video introduced you to our PACE apparatus in further detail.
This image shows our PACE device, with two turbidostats and two lagoons. All tubings are color coded and equivalent to the tubings shown in the scheme in Fig. 3.
This picture is showing the second part of the construction of our PACE device. The syringe pumps (green) as well as the valve control and the oxygen supply are shown. All necessary tubings and cables are inserted in the heating cabinet.
Our PACE protocol
Before starting a PACE run, several prerequisites have to be fulfilled. Most of the preparations for the different PACE runs are the same in terms of tests for MP activity, F-Pilus plasmids and contamination. Additionally, several pre-tests are recommended to test the APs activity and the general functionality of the implemented genetic circuit.- Every part of the PACE device including all tubings and connectors have to be autoclaved. All open ends should be wrapped in aluminium foil. It is important to check all ends and tubings to be closed before start the dry autoclavation (Be aware of autoclaving only autoclavable parts of the PACE device).
- After autoclavation, the PACE device should be treated with highest carefulness to prevent phage contamination in the turbidostat. To make this possible, the use of 10% H2O2 or incidin as well as the usage of gloves is advised.
- Rebuild the PACE apparatus carefully using incidin to desinfect all for the autoclavation wrapped and thereby closed ends. Connect all necessary parts of the tubings.
- The medium should be prepared slightly different to the medium used in literature [Esvelt et al., 2011] by mixing 140g dikaliumhydrogenphosphate with 40g kaliumdihydrogenphosphate, 20g ammoniumsulfate and 20 ml tween-80 in 20l dH20. The medium should be autoclaved as well before using it.
- the autoclaved medium should be mixed with medium supplements, which should be prepared during autoclavation. 20g glucose, as well as 10g sodium citrate, 0.5g L-leucin, 0.5g and 100g casamino acids or trypton from casein have to be solved in at last 500 ml dH20. If the chemicals cannot be dissolved in this volume, water can be added until it can be solved. The resulting solution have to be sterile filtrated.
- the appropiate volume of the prepared supplements can now be added to the autoclaved medium. This should be implemented in as steril conditions as possible, using incidin to sterilize the used pipette. In addition to the supplements, the appropiate antibiotics have to be added into the medium. Final concentrations should be choosen according the stock concentrations proposed by addgene. A blank for the OD600 measurements should be taken before connecting the medium to the tubings.
- After connecting the media line of the turbidostat to the medium container, the turbidostat should be filled with medium until a volume of 1.5 l is reached, by starting the media pump.
- 50 ml bacterial culture resulting from the *MP testing* should be used for inoculation. Therefore draw up the culture into a syringe and inoculate the turbidostat using a cannula through the septa in the turbidostat. Reduce the flow rate to a minimum to ensure an efficient growth of the culture in the turbidostat.
- lagoon pump can be started when the turbidostat reaches an OD600 = 0.6 - 1.0. The lagoon volume can be adjusted at a range of 100 - 150 ml lagoon volume.
- induce mutagenesis by start adding 10% w/v arabinose to the lagoon. Arabinose should be added at last one hour before infection with bacteriophages to secure the induction of the MPs
- When the lagoon is ready, arabinose is added and the cells are on a constant optical density, the lagoon can be infected with bacteriophages. Add 1 ml of 1010 PFU/ml to the lagoon and start the existing PACE run
- During the PACE run, samples should be taken every four hours for the first 24 hours and every eight hours from the second day on until the run is finished. Also, phage detection PCRs and plaque assays should be implemented, proving the presence of the phage of interest and a contamination free turbidostat. Positive and negative control always have to be included into the detection PCR as well as the plaque assays.
Results – evolving split T7 polymerase toward improved auto-reassembly
We set out to employ PACE for evolving a split T7 polymerase towards increased auto-reassembly. Details on the how we obtained the particular split variant used in this PACE experiment can be found on our Protein Interaction subpage. In brief, based on the paper by Tiun Han et al.
During the PACE run continuously monitored the phage titer as well as optical density of our E. coli hosts (Figure 7). The used flow rate was approximately 1 lagoon volume per hour and adapted according to the optical density measurements.
After having finished our PACE run, we performed plague assays and PCR amplified the Split T7 genes from 5 different plagues followed by sanger-sequenced. As hoped, we observed a recurrent, coding mutation (T877P) present in three out of the five sequenced split T7 variants (Figure 8).
Interestingly this residue is located very close to the interaction surface of the two split T7 domains, suggesting a possible role in T7 auto-reassembly (Figure 9).
Discussion
For discussion about the obtained, recurrent split T7 mutation and its possible role in split domain auto-reassembly, please refer to the protein interaction subpage. In this subproject, we sought out to set up PACE in our lab. Initially, we aimed at reproducing a previously described experimentTroubleshooting
Evolving a split T7 Polymerase -PACE
Based on the high-potential concept of Phage-assisted continous evolution the group of Bryan Dickinson evolved a T7 RNA polymerase in the "Evolution of a split RNA polymerase as a versatile biosensor platform"-paper, publicated in early 2017- phage washout
- turbidostat contamination and working without contamination
- flow rates
- induction of mutagenesis
- evaluation of successfully performed PACE
Random-mutagenesis PACE
Following our first PACE tests based on the the split T7 RNAP paper, we designed a new PACE test, using our modeling to estimate the glucose concentration in the lagoons as well as in the turbidostat. First tested in a pre-test using PREDCEL, we tried to transfer equivalent conditions yielding mutations in PREDCEL on the PACE apparatus. In order to do that, an alternative bacterial strain which contains the pJC175e plasmid, a plasmid usually used for plaque assays, providing geneIII under a psp-promotor for all phages was used. In addition to this propagation plasmid, MP1 and MP4 were transformed into one strain respectively. These strains were used for propagation of phages, used for the Dickinson-PACE testing too. Since the Dickinson-phage propagates in previously performed pre-experiments very well, the effect of the concurrent performed propagation and mutagenesis should be at its maximum. This is further underlined by the fact that in this case, geneIII is provided for free. Thus, there should be no selection pressure except from pressure on the best propagation regarding codon optimisation. Beyond that, a lot of random mutations should be observed when the MPs work reliable. To reach this point, three days of mutations using the MP1 and the MP4 strain simultanously in two turbidostats with one lagoon for each turbidostat were implemented. Sequencings were performed by picking eight plaques of each lagoon from the last sample included into the plaque assay. In this case, phage washout was not observed, displaying a phage titer which were settled between 10^4 and 10^7 in both lagoons.PI-PACE
Coming to our final experiment we finally had the knowledge which is required to perform our own PACE run. This PACE run is just like Dickinson´s PACE approach based on protein-interaction of a split T7 RNAP. In contrast to the run before, both split sites are located on the selection phage. In principle, the split T7 RNAP is evolved on a better and faster reassembly of both fragments, yielding in a higher transcription of geneIII which is encoded under control of a T7 promotor. For further information on the principle of protein-interaction PACE, please visit our special site (hier Link einfügen). Building up on the equivalent conditions to the random-mutagenesis PACE run, we used the same amount of glucose and arabinose for induction of the mutagenesis plasmids. In this case, we only used a strain with MP4 due to the observation of slightly more mutations in the random mutagenesis experiment. Since this PACE experiment was performed with selection pressure, we estimated for difficulties in the phage propagation during PACE, which is why the flow rate was decreased for enabling better phage propagation. Nevertheless, our plaque assays showed phage washout after only 38 hours. Regardless of these findings, plaque PCRs and sequencings were performed, using plaques from the last available time point. The sequencing results showed one mutation in each of the split sites, of which one mutation could have a functional input on the reassembly of both sites.Table 1: Documentation of performed tasks with comments
TIme | Date | Operator | Sample | Action | DONE ToDo: | OD Turbidostat 2 | Stock ID | TO DOs: | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
12:00 | 24/10/2017 | MP | - | Started filling the turbidostat (T2) with medium | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||||
13:30 | 24/10/2017 | MP | - | Inoculation of turbidostat 2 with 50 ml Stock culture | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||||
14:00 | 24/10/2017 | MP | - | Measured OD | "0 | 18" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||
15:00 | 24/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
16:00 | 24/10/2017 | MP | - | Measured OD | "0 | 511" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||
17:00 | 24/10/2017 | MP | "Measured OD | started filling the lagoon and the arabinose pump" | "0 | 548" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||
18:00 | 24/10/2017 | MP | 1 | Inoculation with 1 ml phage supernatant | "0 | 514" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||
19:00 | 24/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
20:00 | 24/10/2017 | MS | 1 | "Measured OD | Took samples L1 | T1 - 1" | "0 | 637" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||
21:00 | 24/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
22:00 | 24/10/2017 | MP | "Measured OD | Flow rate for lagoon was to high from previous filling ( 7 ml/min in contrast to 1 | 666 ml/min) - potential washout " | "0 | 791" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||
23:00 | 24/10/2017 | MP | "Lagoon was infected with 0 | 8 ml 10^8 PFU/ml phages to counteract the potential washout " | "0 | 818" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||
00:00 | 25/10/2017 | MP | 2 | "Measured OD | Took samples L1 | T1 - 2" | "0 | 833" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Phage-PCR | ||
01:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
02:00 | 25/10/2017 | MS | Measured OD | "0 | 789" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
03:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
04:00 | 25/10/2017 | MS | 3 | "Measured OD | Took samples L1 | T1 - 3" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||
05:00 | 25/10/2017 | "0 | 792" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||
06:00 | 25/10/2017 | MS | Measured OD | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||
07:00 | 25/10/2017 | "0 | 817" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||
08:00 | 25/10/2017 | TB | 4 | "Measured OD | Took samples L1 | T1 - 4" | Took samples | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||
09:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
10:00 | 25/10/2017 | TB | Measured OD | "0 | 816" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
11:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
12:00 | 25/10/2017 | TB | Measured OD | Done PCR | "0 | 81" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Phage-PCR | ||||
13:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
14:00 | 25/10/2017 | PP | Measured OD | "0 | 843" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
15:00 | 25/10/2017 | inoculated growth for plaque assay | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||||||
16:00 | 25/10/2017 | PP | 5 | "Measured OD | Took samples L1 | T1 - 5" | "0 | 833" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||
17:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
18:00 | 25/10/2017 | PP | Measured OD | "0 | 836" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
19:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
20:00 | 25/10/2017 | MP | Measured OD | "0 | 862" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Plaque Assay | |||||
21:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
22:00 | 25/10/2017 | MP | Measured OD | "0 | 81" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
23:00 | 25/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
00:00 | 26/10/2017 | LP | 6 | "Measured OD | Took samples L1 | T1 - 6" | Done PCR | "0 | 809" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Phage-PCR | |
01:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
02:00 | 26/10/2017 | CG | Measured OD | "0 | 845" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
03:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
04:00 | 26/10/2017 | CG | Measured OD | "0 | 864" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
05:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
06:00 | 26/10/2017 | CG | Measured OD | "0 | 836" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
07:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
08:00 | 26/10/2017 | TB | 7 | "Measured OD | Took samples L1 | T1 - 7" | "0 | 831" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||
09:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
10:00 | 26/10/2017 | TB | Measured OD | "0 | 827" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
11:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
12:00 | 26/10/2017 | TB | Measured OD | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Phage-PCR | |||||||
13:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
14:00 | 26/10/2017 | TB | Measured OD | "0 | 738" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
15:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
16:00 | 26/10/2017 | TB | 8 | "Measured OD | Took samples L1 | T1 - 8" | "Took samples L1 | T1" | "0 | 652" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |
17:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
18:00 | 26/10/2017 | Measured OD | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||||||
19:00 | 26/10/2017 | MS | "0 | 582" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||||
20:00 | 26/10/2017 | Measured OD | Plaque assay was performed successfully | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Plaque Assay | |||||||
21:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
22:00 | 26/10/2017 | MS | Measured OD | "0 | 633" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
23:00 | 26/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
00:00 | 27/10/2017 | PP | 9 | "Measured OD | Took samples L1 | T1 - 9" | "0 | 511" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Phage-PCR | ||
01:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
02:00 | 27/10/2017 | MS | Measured OD | "0 | 692" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
03:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
04:00 | 27/10/2017 | MS | Measured OD | "0 | 937" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
05:00 | 27/10/2017 | "0 | 945" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||
06:00 | 27/10/2017 | MP | Measured OD | "could not be measured | as lagoon medium level was too high and therefore pump where set off for a short time " | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
07:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
08:00 | 27/10/2017 | MS | 10 | "Measured OD | Took samples L1 | T1 - 10" | "Phage detection PCR with samples 8 | 9 and 10 for Dickinson-Phage and PI-Phage" | "0 | 912" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |
09:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
10:00 | 27/10/2017 | PP | Measured OD | "0 | 903" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
11:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
12:00 | 27/10/2017 | LP | Measured OD | see above | "0 | 924" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Phage-PCR | ||||
13:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
14:00 | 27/10/2017 | MP | Measured OD | "0 | 942" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
15:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
16:00 | 27/10/2017 | PP | 11 | "Measured OD | Took samples L1 | T1 - 11" | took samples | "0 | 942" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||
17:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
18:00 | 27/10/2017 | MP | Measured OD | "0 | 822" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
19:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
20:00 | 27/10/2017 | MK | Measured OD | "0 | 59" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Plaque Assay | |||||
21:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
22:00 | 27/10/2017 | CG | Measured OD | "0 | 61" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
23:00 | 27/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
00:00 | 28/10/2017 | MP | 12 | "Measured OD | Took samples L1 | T1 - 12" | Phage detection PCR with sample 11 | "0 | 664" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Phage-PCR | |
01:00 | 28/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
02:00 | 28/10/2017 | CG | Measured OD | "0 | 809" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
03:00 | 28/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
04:00 | 28/10/2017 | MP | Measured OD | PCR: negative - phage washout | "0 | 820" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||
05:00 | 28/10/2017 | "Flow rate was adjusted: 1 ml/min | lagoon was infected by pooled samples 6 | 7 and 8 " | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||||||
06:00 | 28/10/2017 | MP | Measured OD | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||
07:00 | 28/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
08:00 | 28/10/2017 | MP | 13 | "Measured OD | Took samples L1 | T1 - 13" | "0 | 667" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | |||
09:00 | 28/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
10:00 | 28/10/2017 | PP | Measured OD | "0 | 62" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||
11:00 | 28/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
12:00 | 28/10/2017 | PP | Measured OD | Phage PCR was performed | "0 | 768" | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | TO DO: Phage-PCR | ||||
13:00 | 28/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
14:00 | 28/10/2017 | PP | Measured OD | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||
15:00 | 28/10/2017 | 199 (pMax69 aka AP-SplitT7 + GenIII+YFP + MP4) | ||||||||||
16:00 | 28/10/2017 | PP | 14 | "Measured OD | Took samples L1 | T1 - 14" | FINAL PROBES |